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Despite the strong association of asbestos exposure to mesothelioma, only a fraction of
persons exposed develop this neoplasm which is characterized by long latency and
shortened survival. Familial clustering implicates both exposure and genetic predisposition
as causative, but a biologically relevant mesothelioma phenotype essential to genetic
analysis has not been defined. To identify a more extensive set of traits that would define a
mesothelioma phenotype for the purpose of genetic analysis, we set to determine
characteristics that distinguish mesothelioma patients from others exposed to asbestos
and to identify factors that predict the presence of mesothelioma over other mesenchymal
tumors of the peritoneum and carcinoma metastatic to the pleura. We compared
demographics in four asbestos-exposed groups (controls n ¼ 347, bronchogenic cancer
n ¼ 67, mesothelioma n ¼ 179 and benign asbestos-induced lung disease (BALD) n ¼ 3757).
Within the mesothelioma group, we compared traits to identify characteristics associated
with shortened survival. We found that compared to other asbestos-exposed groups,
subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a
second cancer diagnosis (odds ratio ¼ 3.29), had a longer disease latency, and had a
greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI
2.5–3.5). Thoracic tumor location, work exposure and male gender were consistently
associated with shortened survival (1.971.3 years). We conclude that thoracic tumor
location, work exposure, male gender, long latency, early age at first exposure, presence
of a second cancer, and first-degree relative with cancer define a phenotype that sets
mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
We propose that this phenotype be applied to candidate gene analysis.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
716 8426; fax: +1 336 716 7277.
(J.A. Ohar).
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Asbestos exposure can cause asbestosis, benign pleural
disease, lung cancer and mesothelioma. Only a small portion
of exposed individuals develop an asbestos-related disease
and a still smaller fraction develops mesothelioma. In spite
of the large number of exposures, malignant mesothelioma
is a rare disorder with 2000–3000 new cases reported
annually in the US.1 Tragically, patients with mesothelioma
have a median survival of 12 months and rarely survive
greater than 2 years after diagnosis despite vigorous
therapy.2–4 A history of asbestos exposure can be elicited
in more than 80% of mesothelioma patients, and long
latency is the only demographic that reportedly sets
mesothelioma victims apart from other asbestos-exposed
individuals.5–7
Mesothelioma may have a familial distribution, suggesting
a genetic role in its development.8–11 Genes located at 1p,
6q 9p, 13q and 14q have been implicated in familial clusters
of mesothelioma.12,13 Development of mesothelioma is
likely the result of a complex interaction among multiple
genes, host factors and the environment as seen in chronic
obstructive pulmonary disease and asthma.11,14,15 Identifi-
cation of such genes requires rigorous phenotypic classifica-
tion, but such a comprehensive system is not currently
available. We believe that a clinically meaningful phenotype
must incorporate salient features of this disease, including
the heterogeneity of biological responses to asbestos, the
long latency in development of mesothelioma, and the
abbreviated survival associated with this neoplasm. To
delineate a set of traits that would define a mesothelioma
phenotype essential to genetic analysis, we set two
specific aims: to identify characteristics that (1) distinguish
mesothelioma patients from others exposed to asbestos and
that (2) predict the presence of mesothelioma over
other mesenchymal tumors of the peritoneum and
cancer metastatic to the pleura. To determine character-
istics that distinguish mesothelioma patients from
others exposed to asbestos, we report demographic data
from 179 subjects diagnosed with mesothelioma
compared with data from similarly exposed subjects with
asbestos-induced bronchogenic cancer, benign asbestos-
induced lung disease (BALD) and exposed subjects
that were free of demonstrable asbestos-induced disease
(controls). Because shortened survival is the only previously
reported condition that suggests mesothelioma over other
mesenchymal tumors of the peritoneum and metastatic
cancer to the pleura,7,16 we compared traits within the
mesothelioma group to find those associated with shortened
survival.Methods
Asbestos-exposure histories, demographic characteristics,
personal and family medical history of 4350 consecutive
referrals for independent medical evaluation (IME) were
compared. Mesothelioma patients (n ¼ 179) were compared
to subjects who were free of radiologically detectable
asbestos-induced disease (controls n ¼ 347), or had benign
radiographic manifestations of their asbestos exposure
(BALD n ¼ 3757) or lung cancer (LC n ¼ 67). BALD refers toall nonmalignant asbestos-related disease defined by the
American Thoracic Society as: asbestosis, pleural thickening
or asbestos-related pleural fibrosis (plaques or diffuse
fibrosis).17 The details of this population have already been
reported.18 A chest X-ray and an extensive questionnaire
were obtained as part of the referral process.B-readings and ILO scores
Chest X-rays were performed and interpreted by one of
several certified B-readers.18 X-rays were also reread by a
single non-B-reader physician investigator. Chest X-ray
abnormalities were quantified by the B-reader according
to the International Labor Organization (ILO) scoring
system.19 Subjects who were classified as controls due to
lack of radiographic findings were recruited through the
same mechanisms, worked in the same trades and for the
same duration as other subjects. Controls, however, were
screened on two separate occasions, at least 10 years apart
to exclude subclinical or slowly evolving asbestos-induced
lung disease that was not apparent at the time of the first
evaluation. To qualify as a control, the chest X-ray had to be
completely free of asbestos-induced abnormalities on both
occasions.Asbestos exposure and health history questionnaire
Detailed information about prior employment, smoking
history, personal and family health history was obtained
using a self-administered questionnaire. Subjects quantified
their tobacco use according to method of smoking (cigar-
ette, cigar, or pipe), packs per day, age of initiation and
cessation of tobacco use. Subjects listed every job since
completion of schooling (name of company, job title and
tasks performed). Personal health history questions included
a listing of all medications and hospitalizations including
dates of confinement and diagnoses. A personal history of
cardiovascular, other respiratory diseases and the occur-
rence of cancer were obtained. Subjects were asked the age
and cause of death of their parents and siblings. A family
history of cancer was queried. Other questions included the
year of first exposure to asbestos and employment in trades
or at locations known to be associated with asbestos
exposure. Asbestos exposure qualified as ‘‘occupational’’
when it entailed working directly with or beside tradesmen
working directly with asbestos-containing materials. Expo-
sure was deemed ‘‘bystander’’ if asbestos dust was brought
home on work clothing, through ambient air currents from a
neighborhood factory or household remodeling.20–25 All
questionnaire responses were discussed and verified with
the patient by the physician investigator (JO) at the time of
the evaluation.
Survival after diagnosis of mesothelioma was calculated
as the time in years between the date of diagnosis and the
date of death. For mesothelioma subjects surviving at the
time of analysis (September 2005) survival was calculated as
the time in years between the date of diagnosis and the date
of analysis.
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To support the two specific aims the data were analyzed two
ways; among groups and between groups. To determine
traits that set mesothelioma victims apart from others
exposed to asbestos, subjects were grouped by clinical
condition into one of four categories: mesothelioma, lung
cancer, BALD and controls. Variables assessed included
gender, age at first exposure, latency, history of cigarette
smoking, pack/years of cigarette exposure, personal history
of cancer, family history of cancer, education, job classifica-
tion and milieu of exposure based on whether exposure was
occupational or bystander. Variables were compared among
the four clinical groups (mesothelioma, lung cancer, BALD
and controls) and differences for continuous variables were
determined by analysis of variance (ANOVA). Significance of
differences was determined by Tukey–Kramer post hoc
testing. Categorical variables were compared using w2.
Because survival may predict the presence of mesothe-
lioma over other mesenchymal tumors of the peritoneum
and cancer metastatic to the pleura, the second aim was to
identify traits that were associated with a shortened
survival among mesothelioma patients. The variables listed
above and the following characteristics were compared
between the mesothelioma groups: type of exposure
(occupational or bystander) location of tumor (pleural vs.
peritoneal), gender, cell type (epithelial, sarcomatoid, and
biphasic), age at first exposure, latency, survival and family
history of cancer. A set of algorithms was then constructed
to define a subset of mesothelioma subjects with shortened
survival to be used in combination with the demographic
traits found to identify asbestos-exposed individuals at
greatest risk for mesothelioma.
Results
Variables that distinguish mesothelioma subjects
from other asbestos-exposed groups
Subjects with mesothelioma were first exposed to asbestos
at an earlier age than all other groups (Table 1). When
bystander-exposed mesothelioma subjects were excluded
from the analysis, a significant difference in age at first
exposure to asbestos persisted between occupationally
exposed mesothelioma subjects and BALD (19.375.1 vs.
23.676.5 years, respectively, Po0.0001). Because the ageTable 1 Subjects with mesothelioma were exposed early, had
Mesothelioma L
Age at first exposure (years) 16.3 (8.1) 2
Latency (years) 47.9 (11) 4
Age at diagnosis (years) 64.2 (13.5) 6
Pack years 31.1z (37.8) 5
Data reported as mean (SD).
Po0.001 vs. all others.
Po0.0005 vs. controls.
yPo0.01 vs. all others.
zPo0.005 vs. BALD.at diagnosis was similar for all groups, mesothelioma
subjects had a significantly greater latency compared with
all other groups.
Subjects with cancer (mesothelioma and lung cancer) had
a significantly (odds ratio estimate ¼ 3.29 (2.3–4.7) 95% CI
Po0.0001) greater risk of an additional second cancer
diagnosis compared with subjects without cancer (BALD and
controls). The most common second primary cancer in
mesothelioma patients was prostate cancer. The point
estimate for risk of a first degree relative of a mesothelioma
patient having cancer was 2.93 (95% CI 2.5–3.5) compared
with first-degree relatives of subjects with lung cancer,
BALD, or controls. When first-degree relatives were char-
acterized further as siblings, children and parents of a
mesothelioma patient the point estimate for risk of having
cancer was 2.9 (2.38–3.54; 95% CI), 6.75 (3.0–15.1; 95% CI)
and 2.3 (1.77–2.96; 95% CI), respectively, compared with
first-degree relatives of subjects with BALD. Gastro-intest-
inal neoplasia was the most common cancer type among
first-degree relatives of mesothelioma patients.
Mesothelioma patients were slightly more educated
(12.672.6 years) compared with subjects with lung cancer,
BALD and controls (10.372.5, 11.272.0 and 11.472.1
years of schooling, respectively: Po0.001). The mean ILO
score expressed on a continuous linear scale revealed no
significant differences between mesothelioma, lung cancer
and BALD. Mesothelioma patients smoked less than subjects
with lung cancer and BALD but not controls (Table 1).
Twenty-seven percent of mesothelioma patients never
smoked compared with less than 1% of subjects with BALD
and 1% of controls. All subjects with lung cancer smoked.Mesothelioma phenotype that predicts survival
Mean survival after diagnosis for mesothelioma subjects was
1.971.3 years. Predictors for a shortened survival within
the mesothelioma group were thoracic location or work
exposure or male gender (Table 2). Based on these variables,
three sets of algorithms were created to identify a
mesothelioma phenotype with characteristics that pre-
dicted survival (Table 3). Whatever the order in which they
were implemented, the same 166 subjects were identified
with each algorithm with a mean survival post-diagnosis of
1.8271.3 years. The 13 subjects consistently excluded by
this algorithm (mean survival post-diagnosis of 3.171.3
years) had bystander exposures and peritoneal tumora longer latency and smoked less than comparators.
ung cancer Benign asbestos Control
3.7 (7.8) 23.6 (6.5) 23.1 (6.6)
0 (10) 41 (10.3) 39 (10.5)
4 (8.9) 64.6 (9.8) 62.2 (10.2)
5.6y (35.1) 41.8 (33.9) 34.8 (46.1)
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Table 2 Thoracic location, male gender, and occupational exposure predict shorten survival.
Location Exposure Gender Cell type
Survival Peritoneal Thoracic Work Bystander M F Epith Non
42 years 16 (76) 52 (32) 40 (31) 28 (55) 43 (31) 25 (51) 58 (44) 9 (23)
p2 years 5 (24) 106 (68) 88 (65) 23 (45) 92 (69) 19 (41) 71 (56) 30 (77)
Total 21 158 128 51 135 44 129 39
p ¼ 0.0002 p ¼ 0.0033 p ¼ 0.003 p ¼ 0.0145
Data reported as n (%).
Table 3 Peritoneal mesotheliomas were significantly younger at the time of first exposure, more likely the result of
bystander exposure and experienced shorter latencies than pleural mesotheliomas.
Exposure type Tumor location Sex
Occupational Bystander Pleural Peritoneal Male Female
n (%) 128 (72) 51 (28) 158 (88) 21 (12) 135 (75) 44 (25)
Age @ first exposure (years) (mean7SD) 19.3 (5.1) 8.6 (9.5)z 17 (7.6) 11.4 (10.3) 17.9 (6.2) 11.5 (11)
Latency (y) (mean7SD) 49.2 (9.6) 44.5 (13.5)y 49.2 (10.1) 38.9 (13.1) 49.1 (10) 44.5 (13.1)
Age at diagnosis (years) (mean7SD) 68.5 (10.3) 53.7 (14.9)z 50.3 (16) 66.1 (12) 66.9 (11.6) 56 (15.4)
Sex
Male n (%) 118 (87) 17 (13)z 127 (94.1) 8 (5.9)
Female n (%) 10 (23) 34 (77)z 21 (70.5) 13 (29.5)
Tumor location
Pleural n (%) 122 (95.3) 6 (4.7)
Peritoneal n (%) 36 (70.6) 15 (29.4)






Table 4 Mesothelioma phenotype proposed for genetic
J.A. Ohar et al.506location. Those excluded may represent individuals with







 Cancer in first-degree relative
Tumor factors:
 Thoracic location
 Long latencyOther demographics of the mesothelioma
population
African Americans were under represented in the cohort but
were distributed equally among the four groups
(mesothelioma ¼ 3.4%, lung cancer ¼ 6.0%, BALD ¼ 6.4%
and controls ¼ 8.9%). Men accounted for 96.2% of the cohort
however; there was a greater proportion of women
(Po0.0001) in the mesothelioma group (24.6%) than in
subjects referred for other asbestos-induced disorders.
Female mesothelioma subjects were first exposed to
asbestos at an earlier age and had a shorter latency than
males (Table 4).
ARTICLE IN PRESS
Identification of a Mesothelioma phenotype 507There were significantly more women than men in the
bystander group. Age at first exposure was significantly less
for individuals exposed as bystanders, but latency tended
also to be shorter in bystander (Po0.05) compared to
occupational exposure. Peritoneal mesotheliomas were
more likely the result of bystander exposure than occupa-
tional exposure, whereby pleural mesothelioma was more
frequently associated with occupational type exposures
(Table 4). Subjects with peritoneal mesotheliomas were
significantly younger at the time of first exposure to asbestos
and experienced shorter latencies than subjects with pleural
mesothelioma (Table 4). There was no significant association
between gender, location or exposure milieu and mesothe-
lioma cell type (epithelioid, sarcomatous or biphasic).
Mesothelioma was diagnosed by cytologic examination
and not typed in 11 subjects (6%). Pathologic examination of
the remaining 168 subjects revealed the cell type to be
epithelioid in 129 (77%), sarcomatoid in 16 (9%) and biphasic
in 23 (14%). Although the commonest cell type in both men
and women was epithelioid, there was a trend (P ¼ 0:06)
toward men more frequently having the sarcomatous cell
type than women and the inverse with biphasic type.
Latency was longer for subjects with the sarcomatous cell
type compared with the epithelioid cell type of mesothe-
lioma (54.176.1 vs. 47.1711.4 years). There was no effect
of location (pleural vs. peritoneal) or exposure milieu
(occupational vs. bystander) on cell type.Discussion
The object of this study was to characterize a mesothelioma
phenotype that distinguished mesothelioma patients from
other asbestos-exposed study participants and predicted the
presence of mesothelioma over other mesenchymal tumors
of the peritoneum or cancer metastatic to the pleura to be
used in future candidate gene analysis. While familial
distributions of mesothelioma have been described, genetic
association studies for mesothelioma have yielded conflict-
ing results. Hirvonen et al.26,27 found an association
between asbestos-related pulmonary disorders and GST
mu, but only when coupled with an N-acetyl transferase
(NAT) 2 slow-acetylator genotype. More recently, Neri et
al.28 found an increased odds ratio for mesothelioma in
subjects who had genotypic low microsomal epoxide
hydrolase activity. They also demonstrated augmentation
of risk in subjects with NAT fast acetylator or glutathione-S-
transferase mu null genotypes in combination with geno-
typic low microsomal epoxide hydrolase activity.28 Stucker
et al.29 using pooled data from the Genetic Susceptibility
and Environmental Carcinogens International Database,
found no association between asbestos exposure and GST
mu and t genotypes and asbestos-induced carcinogenesis.
The mixed results of these susceptibility studies may be the
result of failure to rigorously phenotype participants. This
challenging task must take into account the variable clinical
responses to asbestos exposure and biologic behavior of
mesothelioma.
To date, only long latency and shortened survival have
been consistently reported as hallmarks of the mesothelio-
ma phenotype.2–6 We confirmed the long latency associa-
tion. Moreover, we found that subjects with mesotheliomawere younger at first asbestos exposure, had a greater risk
of a second cancer diagnosis and had a greater risk to cancer
for first-degree relatives. Furthermore, we found that
thoracic tumor location, work (vs. bystanders) exposure
and male gender-predicted shortened survival. The link
between early age at first exposure to asbestos and
mesothelioma in our data set persisted even after patients
with bystander exposures were excluded from the analysis.
We could find one other report in the literature associat-
ing age at first exposure to asbestos to risk for mesothelioma
and this was in animals.30 Berry and coworkers demon-
strated in rats that early age of inoculation was a significant
risk factor for mesothelioma. In contrast to our observa-
tions, Peto and coworkers found that age at first exposure
was not an independent risk factor; however, Peto et al.31
focused on occupationally exposed individuals with the
youngest age at exposure being 15 years. The obvious
explanation for early exposure as a mesothelioma risk is that
immature lungs have increased sensitivity to carcinogens.
Alternatively, it is possible that the smaller airways of
children and women retain more fibers than do the larger
airways of adults, especially men. Becklake et al.32 and
coworkers suggested that body size is a factor in mesothe-
lioma development.33
While others have reported that mesothelioma patients
experience a longer latency, smoked less and had first-
degree relatives that developed cancer more frequently
than asbestos-exposed comparators,34–41 major new findings
in our data set are that subjects with mesothelioma are
exposed to asbestos at an earlier age and had a second
cancer diagnosed more frequently than other asbestos-
exposed groups. When first-degree relatives were further
separated into siblings, parents and children of mesothelio-
ma subjects, a startling increase in risk for cancer became
apparent for children. Taken together, the observations that
first-degree relatives of mesothelioma subjects developed
cancer more frequently and that mesothelioma subjects
develop another cancer other more frequently than com-
parators suggest an increased genetic susceptibility of
mesothelioma subjects to cancer. Vianna and Polan40
postulated such a genetic predisposition to malignant
mesothelioma based on increased frequency of parental
cancer in patients with mesothelioma compared to control
frequencies. The frequency of a parent with malignancy was
17/52 (33%) in a cohort of women with mesothelioma from a
bystander exposure.40 Heineman et al.41 also provided
evidence for family history of cancer being a risk factor
for mesothelioma. The increased likelihood of second
cancers in mesothelioma patients and of cancer among
first-degree relatives is important not only to investigation
of genetic predispositions to neoplasia, but also to the
comprehensive clinical care of mesothelioma patients and
their families.
We conclude that thoracic tumor location, work expo-
sure, male gender, long latency, early age at first exposure,
presence of a second cancer, and first-degree relative with
cancer define a phenotype that sets mesothelioma patients
with a shortened survival apart from other asbestos-exposed
individuals. On the basis of the current observations derived
from this prospectively studied, rigorously defined popula-
tion, we propose the mesothelioma phenotype outlined in
Table 3 for candidate gene analysis. Of these factors, male
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predictors of shorted survival in previous multivariable
analyses of mesothelioma cohorts. In addition, nonepithelial
histology, associated with longer latency in our patients, has
also been associated with worsened prognosis. Importantly,
our shortened survival algorithm which includes thoracic
tumor location, work exposure and male gender will exclude
subjects who sustained a bystander exposure from genetic
analysis. Bystander exposure is a common, clinically
important and infrequently recognized risk for mesothelio-
ma. The presence of a large percentage of women and a high
frequency of bystander exposure distinguishes this mesothe-
lioma cohort from others previously published. We acknowl-
edge that the proposed phenotype represents a starting
point, to be refined further as new analysis and epidemio-
logic investigations become available.Acknowledgements
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